IIT Bombay Grads’ Startup Entvin AI Secures INR 5 Crore Funding from Y Combinator
Mumbai, India – Entvin AI is a cutting-edge startup. It was founded by three IIT Bombay graduates. The startup has secured $500K (INR 5 crore) in its first funding round. The funds were provided by Y Combinator, the world’s most prestigious startup accelerator known for its highly selective 0.1% acceptance rate.
The startup specializes in AI-powered solutions. These are tailored for the pharmaceutical and life sciences industries. They help streamline the complex FDA drug approval process.
Revolutionizing Drug Approvals with AI
Sanskar Jain (CEO), Hemant Phalak (CPO), and Rishabh Arya (CTO) founded Entvin AI. They developed a regulatory compliance platform that automates documentation, compliance checks, and real-time monitoring. These tasks traditionally take thousands of hours for pharmaceutical companies.
With the FDA approval process often taking years and costing millions, inefficiencies can delay life-saving drugs from reaching patients. Entvin’s AI platform tackles this bottleneck by:
- Automating regulatory document drafting
- Identifying compliance gaps in real-time
- Reducing manual workload by hundreds of hours
- Ensuring adherence to FDA and global regulatory standards
Early Success & Enterprise Adoption
The startup has already demonstrated success with pilot customers, showing significant efficiency gains in regulatory workflows. Some clients reported reclaiming hundreds of hours previously spent on manual compliance tasks.
“Regulatory professionals spend countless hours on documentation and compliance checks. Our AI agents streamline these workflows, allowing teams to focus on strategic priorities rather than administrative burdens.” …Sanskar Jain, Co-founder & CEO
“Our AI doesn’t just organize data—it provides actionable insights, automates repetitive tasks, and ensures seamless integration into existing workflows.” …Hemant Phalak, Co-founder & CPO
Next Steps: Scaling AI for Global Pharma
With the Y Combinator backing, Entvin AI plans to:
- Expand AI capabilities for mid-to-large pharmaceutical firms
- Accelerate customer acquisition in global markets
- Enhance enterprise-grade security (SOC 2, ISO 27001 compliance)
“Our AI deeply understands FDA regulations and processes massive volumes of documentation while meeting the highest compliance standards.” Rishabh Arya, Co-founder & CTO
Why This Matters
The pharmaceutical industry loses millions due to regulatory delays. Entvin’s AI-driven approach could shorten approval timelines, cut costs, and ultimately bring critical treatments to patients faster.
Stay updated with the latest in tech and startups—follow our blog for more breaking news!
